CFP last date
22 April 2024
Reseach Article

A Regression Analysis and Study of COX-2 Inhibitors Verified by Phylogenetic Tree

by Chunduru Madhava Rao, Yesu Babu Adimulam
International Journal of Computer Applications
Foundation of Computer Science (FCS), NY, USA
Volume 158 - Number 3
Year of Publication: 2017
Authors: Chunduru Madhava Rao, Yesu Babu Adimulam
10.5120/ijca2017912768

Chunduru Madhava Rao, Yesu Babu Adimulam . A Regression Analysis and Study of COX-2 Inhibitors Verified by Phylogenetic Tree. International Journal of Computer Applications. 158, 3 ( Jan 2017), 23-28. DOI=10.5120/ijca2017912768

@article{ 10.5120/ijca2017912768,
author = { Chunduru Madhava Rao, Yesu Babu Adimulam },
title = { A Regression Analysis and Study of COX-2 Inhibitors Verified by Phylogenetic Tree },
journal = { International Journal of Computer Applications },
issue_date = { Jan 2017 },
volume = { 158 },
number = { 3 },
month = { Jan },
year = { 2017 },
issn = { 0975-8887 },
pages = { 23-28 },
numpages = {9},
url = { https://ijcaonline.org/archives/volume158/number3/26889-2017912768/ },
doi = { 10.5120/ijca2017912768 },
publisher = {Foundation of Computer Science (FCS), NY, USA},
address = {New York, USA}
}
%0 Journal Article
%1 2024-02-07T00:03:51.279762+05:30
%A Chunduru Madhava Rao
%A Yesu Babu Adimulam
%T A Regression Analysis and Study of COX-2 Inhibitors Verified by Phylogenetic Tree
%J International Journal of Computer Applications
%@ 0975-8887
%V 158
%N 3
%P 23-28
%D 2017
%I Foundation of Computer Science (FCS), NY, USA
Abstract

Cyclo-oxygenase-2 (COX-2), a rate-limiting enzyme for prostanoid synthesis, is induced during inflammation and participates in inflammation-mediated cytotoxicity. The discovery of two cyclo-oxygenase (COX) isoenzymes, viz. COX-1 and COX-2, has updated the knowledge of non steroidal anti-inflammatory drugs (NSAIDs). The two COX isoenzymes share structural and enzymatic similarities, but are specifically regulated at the molecular level and may be distinguished apart in their functions, although some physiological overlap between them does occur. The major goal in developing selective COX inhibitors is to improve NSAID tolerability. Conventional non steroidal anti-inflammatory drugs (NSAIDs) nonspecifically inhibit cyclooxygenase-1 (COX-1), an enzyme critical to normal platelet function, and COX-2 which mediates inflammatory response mechanisms. Celecoxib, the 1, 5-diarylpyrazole compounds was the first launched selective COX-2 inhibitor, and has excellent selectivity and potent anti-inflammatory activity. COX-2 is required for both the constitutive and mitogen-induced PGE2 synthesis. Moreover, over-expression and persistent expression of COX-2 may be influenced by breast tumor hormone status and seem to be a feature of the aggressive, metastaticpheno type. Recent studies have indicated that the relationships between polyunsaturated fatty acid metabolism and carcinogenesis have led to new targets for the design of mechanism based drugs in cancer chemoprevention research. Selective inhibition of COX-2 provided a new class of anti inflammatory, analgesic, and antipyretic drugs with significantly reduced side effects. It has been reported that inhibiting COX-2 could also be an important strategy for preventing or treating a number of cancers. COX-2 selective inhibitors such as celecoxib, rofecoxib and valdecoxib are currently being used to reduce inflammatory response. However, they lack anti-thrombotic activity and hence lead to cardiovascular and renal liabilities apart from gastrointestinal irritation. Therefore, there is still a need to develop more potent COX-2 inhibitors. One of the keys to developing COX-2 selective drugs is the larger active site of COX-2, which makes it possible to make molecules too large to fit into the COX-1 active site but still able to fit the COX-2.

References
  1. Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids {Chakraborty, SK Das, J Wang, and SK Dey,}, Journal of Molecular Endocrinology, Vol 16, Issue 2, 107-122.
  2. Yu, Y., J. Fan, Y. Hui, C. A. Rouzer, L. J. Marnett, A. J. Klein-Szanto, A. FitzGerald, and C. D. Funk. 2007. Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. Biol. Chem. 282: 1498–1506.
  3. Ueno, N., Y. Takegoshi, D. Kamei, I. Kudo, and M. Murakami. 2005. Coupling between cyclooxygenases and terminal prostanoid syn-thases. Biochem. Biophys. Res. Commun. 338: 70–76.
  4. Smith, W. L., and R. Langenbach. 2001. Why there are two cyclo-oxygenase isozymes. J. Clin. Invest. 107: 1491–1495.
  5. Laneuville, O., D. K. Breuer, N. Xu, Z. H. Huang, D. A. Gage, J. T. Watson, M. Lagarde, D. L. DeWitt, and W. L. Smith. 1995. Fatty acid substrate specificites of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z,13E/Z,15Z)-octadeca - trienoic acids from a-linolenic acid. J. Biol. Chem. 270: 19330–19336.
  6. Smith, W. L. 2005. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr. Opin. Cell Biol. 17: 174–182.
  7. Serhan, C. N., N. Chiang, and T. E. Van Dyke. 2008. Resolving in-flammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8: 349–361.
  8. Jonathan Baarsch and M. Emre Celebi "Investigation of Internal Validity Measures for K-Means Clustering" in Proceedings of the International Multi conference of Engineers and Computer Scientists 2012 Vol 1, IMCES 2012, March 14-16 2012, HongKong.
  9. Kubinyi H. Variable selection in QSAR studies. II. A Highly Efficient Combination of Systematic Search and Evolution. Quant. Struct. Act. Relat. 13, 1994, 393-401.
  10. Kubinyi H. Variable selection in QSAR studies. I. An evolutionary algorithm. Quant. Struct. Act. Relat. 13, 1994, 285-294.
  11. www.arkat-usa.org
  12. Ruth Pérez-Fernández, Pilar Goya, and José Elguero. A review of recent progress (2002-2012) on the biological activities of pyrazoles. ARKIVOC 2014 (ii) 233-293.
Index Terms

Computer Science
Information Sciences

Keywords

COX-2 Phylogenetic tree Correlation Inhibitors.